L

    Lineage Cell Therapeutics Inc (LCTX)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • AMEX

    $1.10
    -0.01 (-0.90%)

    Market Cap: $280.73M

    Last updated: Sep 01, 2026 at 10:00 AM ET

    Earnings

    Performance (10Y)

    Beat Rate
    68%(27/40)
    Avg Surprise
    -16.14%
    Streak
    1 Q

    Upcoming Estimates

    Sep 30, 2026
    EPS Consensus$-0.04
    Range$-0.04 - $-0.03
    4 analysts
    EPS RevisionsNo revisions (7d)
    0
    1
    30d
    EPS Estimate Drift
    90d ago$-0.03+20.0%
    60d ago$-0.03+14.3%
    30d ago$-0.03+14.3%
    7d ago$-0.03+14.3%
    Current$-0.04
    Revenue Consensus
    $1M
    Range$0 - $2M
    6 analysts
    Dec 31, 2026
    EPS Consensus$0.03
    Range$-0.04 - $0.13
    5 analysts
    Revenue Consensus
    $10M
    Range$-2885000 - $31M
    7 analysts
    PeriodReportedEst.SurpriseB/MYoY
    Dec 26EST
    		-$0.03---
    Sep 26EST
    		-$-0.04---
    Jun 26
    		$-0.03$-0.03+0.00%Beat+76.9%
    Mar 26
    		$-0.03$-0.02-36.50%Miss-36.5%
    Dec 25
    		$0.00N/A+108.75%Beat+135.0%
    Sep 25
    		$-0.13$-0.03-333.33%Miss-550.0%
    Jun 25
    		$-0.13$-0.03-333.33%Miss-333.3%
    Mar 25
    		$-0.02$-0.03+33.33%Beat+50.0%
    Dec 24
    		$-0.01N/A+66.67%Beat+66.7%
    Sep 24
    		$-0.02$-0.03+33.33%Beat+50.0%
    Jun 24
    		$-0.03$-0.04+25.00%Beat+0.0%
    Mar 24
    		$-0.04$-0.04+0.00%Beat-33.3%
    Dec 23
    		$-0.03$-0.04+25.00%Beat+0.0%
    Sep 23
    		$-0.04$-0.03-33.33%Miss-33.3%
    Jun 23
    		$-0.03$-0.04+25.00%Beat+25.0%
    Mar 23
    		$-0.03$-0.05+40.00%Beat+25.0%
    Dec 22
    		$-0.03$-0.04+25.00%Beat+82.4%
    Sep 22
    		$-0.03$-0.04+25.00%Beat+0.0%
    Jun 22
    		$-0.04$-0.02-100.00%Miss+0.0%
    Mar 22
    		$-0.04$-0.06+33.33%Beat+20.0%
    Dec 21
    		$-0.17$-0.05-240.00%Miss-1800.0%
    Sep 21
    		$-0.03$-0.05+40.00%Beat+25.0%
    Jun 21
    		$-0.04$-0.04+0.00%Beat-33.3%
    Mar 21
    		$-0.05$-0.04-25.00%Miss+16.7%
    Dec 20
    		$0.01N/A+120.00%Beat+133.3%
    Sep 20
    		$-0.04$-0.04+0.00%Beat+20.0%
    Jun 20
    		$-0.03$-0.05+40.00%Beat+50.0%
    Mar 20
    		$-0.06$-0.03-100.00%Miss-20.0%
    Dec 19
    		$-0.03$-0.05+40.00%Beat+90.6%
    Sep 19
    		$-0.05$-0.05+0.00%Beat+37.5%
    Jun 19
    		$-0.06$-0.05-20.00%Miss+14.3%
    Mar 19
    		$-0.05$-0.06+16.67%Beat+50.0%
    Dec 18
    		$-0.32$-0.07-357.14%Miss+44.8%
    Sep 18
    		$-0.08$-0.06-33.33%Miss-125.8%
    Jun 18
    		$-0.07$-0.09+22.22%Beat-40.0%
    Mar 18
    		$-0.10$-0.07-42.86%Miss-42.9%
    Dec 17
    		$-0.58$-0.07-728.57%Miss-1060.0%
    Sep 17
    		$0.31$-0.08+487.50%Beat+3.3%
    Jun 17
    		$-0.05$-0.09+44.44%Beat-
    Mar 17
    		$-0.07$-0.09+22.22%Beat-
    Dec 16
    		$-0.05N/A+64.29%Beat-
    Sep 16
    		$0.30$-0.10+400.00%Beat-

    Dividends

    Dividend Metrics

    Yield0.00%
    Annual/Share$0.00
    No dividend payments in the selected period.

    Key Metrics

    Valuation
    P/E Ratio-5.98EV/EBITDA-8.84x
    Price/FCF-11.25xFCF Yield-8.89%
    Profitability
    Profit Margin-246.60%Operating Margin-835.00%
    ROE-60.10%ROIC-50.46%
    Financial Health
    Debt/Equity0.00xInterest CoverageN/A
    Current Ratio6.61xQuick Ratio6.61x
    Trading Statistics
    Beta1.55Avg Volume843.53K
    52-Week High$2.0952-Week Low$1.00

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$1.10
    SMA 20$1.10
    SMA 50$1.16
    SMA 200$1.48
    EMA 10$1.11
    EMA 20$1.11
    EMA 50$1.16
    EMA 200$1.32

    MACD

    Line: -0.01Signal: -0.02Hist: 0.01

    ADX

    ADX: 18.8+DI: 18.3-DI: 15.9

    Aroon & PSAR

    Aroon Up92.0
    Aroon DownN/A
    PSAR$1.05

    Bollinger Bands

    Upper Band$1.16
    Lower Band$1.05
    %B Position1040%(Upper)
    Band Width0.47

    RSI (14-Day)

    Neutral
    47.3

    Momentum Oscillators

    Stoch %K57.5
    Stoch %D64.9
    Williams %R-58.6
    ROC (10d)3.8%
    Momentum0.04
    CCI (20d)10.6
    MFI (14d)47.9

    Volatility Measures

    ATR (14d)$0.06(5.0%)
    StdDev (20d)0.03
    Hist Vol37.0%(Moderate)

    Volume Flow

    VWAP$1.11
    OBV41.6M
    AD Line-32.5M
    CMF (20d)-0.137

    Volume Metrics

    Avg Vol (20d)851.7K
    Vol Ratio0.7x
    VWMA (20d)$1.10

    Pivot Points

    R3$1.22
    R2$1.20
    R1$1.15
    Pivot Point$1.13
    S1$1.09
    S2$1.07
    S3$1.02

    Advanced Oscillators

    TSI-5.30
    Ultimate Osc44.2
    KST-45.22

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total Revenue$1.07M$1.73M$6.61M$3.68M$2.77M$1.50M$2.87M$3.78M$1.41M$1.44M$2.09M$1.25M
    Cost of Revenue$0$0$66,000$5,000$39,000$36,000$154,000$38,000$44,000$98,000$256,000$169,000
    Gross Profit$1.07M$1.73M$6.54M$3.68M$2.73M$1.47M$2.71M$3.74M$1.36M$1.35M$1.83M$1.08M
    Operating Expenses$9.99M$9.32M$13.09M$7.46M$22.51M$7.97M$7.82M$7.58M$7.23M$8.01M$8.19M$7.78M
    R&D$4.77M$4.23M$8.24M$3.27M$3.11M$3.11M$3.42M$3.17M$2.87M$3.01M$3.91M$3.74M
    SG&A$5.22M$5.08M$4.85M$4.19M$4.56M$4.86M$4.40M$4.41M$4.36M$5.00M$4.29M$4.04M
    Operating Income$-8,923,000$-7,593,000$-6,548,000$-3,786,000$-19,780,000$-6,505,000$-5,110,000$-3,840,000$-5,867,000$-6,661,000$-6,362,000$-6,705,000
    Interest Income$378,000$405,000$393,000$366,000$454,000$478,000$393,000$397,000$463,000$462,000$404,000$433,000
    Interest Expense$0$0$0$25.97M$0$0$0$0$0$0$0$453,000
    Income Before Tax$0$0$-4,388,000$-29,752,000$0$0$-3,250,000$-3,001,000$-5,773,000$-6,558,000$-4,714,000$-7,158,000
    Income Tax Expense$0$0$0$0$0$0$0$0$0$0$0$0
    Net Income$1.54M$-4,789,000$892,000$-29,752,000$-30,364,000$-4,143,000$-3,250,000$-3,001,000$-5,773,000$-6,558,000$-4,714,000$-7,158,000
    EBITDA$1.35M$-5,006,000$-4,595,000$-29,940,000$-30,647,000$-4,457,000$-3,492,000$-3,257,000$-6,094,000$-6,845,000$-4,943,000$-7,415,000
    EBIT$1.17M$-5,194,000$-4,781,000$-30,118,000$-30,818,000$-4,621,000$-3,643,000$-3,398,000$-6,236,000$-7,020,000$-5,118,000$-7,591,000
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about LCTX

    News

    Lineage Cell Therapeutics (LCTX) Q2 2026 Earnings Call Transcript

    Lineage Cell Therapeutics discussed its "Lineage 3.0" strategy, focusing on its AlloSCOPE platform for scalable, low-cost cell therapies. The company reported Q2 2026 revenues of $1.1 million and a net income of $1.5 million, primarily from a non-cash warrant re-measurement gain. Key program updates included advancements in COR1 for corneal disease, ILT1 for type 1 diabetes manufacturing, and a strategic shift for OPC1 to prioritize chronic spinal cord injury patients, along with ongoing progress in the OpRegen program with Roche.

    The Globe and Mail•8/14/26•
    Bullish

    Lineage Cell Therapeutics (LCTX) Q2 2026 Earnings Call Transcript

    Lineage Cell Therapeutics (LCTX) reported Q2 2026 financial results, highlighting $50.8 million in cash, expected to fund operations into Q3 2028, and a net income of $1.5 million driven by a non-cash gain. The company emphasized its "Lineage 3.0" strategy, focusing on leveraging its AlloSCOPE platform to rapidly develop new cell therapy assets like COR1 for corneal disease, ILT1 for type 1 diabetes, and ReSonance for hearing loss, while also refining its OPC1 program to prioritize chronic spinal cord injury patients. CEO Brian Culley stressed the critical importance of scalable and consistent manufacturing processes for cell therapies from the outset to avoid future development risks.

    The Globe and Mail•8/14/26•
    Somewhat-Bullish

    Lineage Cell Therapeutics Q3 EPS Reduced by HC Wainwright

    HC Wainwright has lowered its Q3 2026 EPS estimate for Lineage Cell Therapeutics (NYSEAMERICAN:LCTX) to a loss of $0.03 per share, down from a previous estimate of $0.01 per share, while maintaining a "Buy" rating. Despite matching EPS expectations, the company's Q3 revenue of $1.07 million missed analyst consensus of $1.84 million. Analyst sentiment remains positive with a consensus price target of $6.25, and institutional investors hold a significant 62.47% stake in the company.

    MarketBeat•8/11/26•
    Neutral

    Lineage Cell Therapeutics Q2 Earnings Call Highlights

    Lineage Cell Therapeutics discussed its Q2 2026 earnings, highlighting progress across its cell-therapy pipeline, including preclinical advances in corneal disease, Type 1 diabetes, and hearing loss. The company emphasized its "Lineage 3.0" strategy focusing on its AlloSCOPE manufacturing platform for scalable, off-the-shelf cell therapies. Lineage reported $50.8 million in cash, extending its runway into Q3 2028, and a net income of $1.5 million for the quarter.

    TradingView•8/10/26•
    Somewhat-Bullish

    Lineage Cell Therapeutics, Inc. (LCTX) stock price, news, quote and history

    This page provides comprehensive information on Lineage Cell Therapeutics, Inc. (LCTX), including its current stock price, historical data, financial overview, and analyst ratings. The company is a clinical-stage biotechnology firm focused on developing cell replacement therapies for various medical conditions, such as age-related macular degeneration and spinal cord injuries. It also details the company's product pipeline, financial performance metrics, and comparisons with similar biotechnology companies.

    Yahoo Finance Australia•8/9/26•
    Neutral

    Frequently Asked Questions About LCTX

    Does LCTX pay dividends?
    Lineage Cell Therapeutics Inc (LCTX) has a dividend payment track record. See the LCTX dividend history page for its current payment status, yield, and streaks.
    What is LCTX's market cap?
    Lineage Cell Therapeutics Inc (LCTX) has a market capitalization of $280.73M with a current stock price of $1.10.

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In